Evenity (Romosozumab) Pediatric (Under 12) Dosing

Why Romosozumab Has No Pediatric Indication

Romosozumab received FDA approval in April 2019 strictly for postmenopausal women with osteoporosis at high risk for fracture [2]. The approval was based on two large Phase 3 trials in adults. Neither the FRAME trial (N=7,180) nor the ARCH trial (N=4,093) enrolled anyone under 55 years old [1][3].

The FDA did not require Amgen to conduct pediatric studies under the Pediatric Research Equity Act (PREA) because the drug's target condition, postmenopausal osteoporosis, does not occur in children. This differs from drugs like denosumab, where the manufacturer eventually pursued pediatric indications for giant cell tumor of bone. Romosozumab's prescribing label includes a single line under Section 8.4 (Pediatric Use): "Safety and effectiveness in pediatric patients have not been established" [2]. No dosing table, no weight-band recommendation, no pharmacokinetic data in children exist in the public domain.

Clinicians treating pediatric bone disorders must recognize this regulatory gap. The absence of data is not the same as evidence of harm, but it is also not permission to extrapolate from adult pharmacology.

The Sclerostin Pathway in Growing Bones

Sclerostin, the protein romosozumab neutralizes, is produced almost exclusively by osteocytes embedded in mature bone [4]. By blocking sclerostin, romosozumab releases the brake on the Wnt signaling pathway, triggering rapid osteoblast-driven bone formation. In postmenopausal adults, this mechanism produced a 13% increase in lumbar spine bone mineral density (BMD) over 12 months in the FRAME trial [3].

Children's skeletons are not miniature adult skeletons. Growth plates (physes) depend on tightly regulated Wnt signaling to coordinate chondrocyte proliferation, hypertrophy, and eventual ossification. Preclinical studies in young rats treated with sclerostin antibodies showed increased trabecular bone volume but also raised questions about whether accelerated modeling could alter longitudinal growth trajectories [5]. The concern is theoretical but biologically plausible: unopposed Wnt activation at the growth plate could accelerate physeal closure or disrupt the balance between bone formation and cartilage turnover.

No human data exist to confirm or refute this risk. That uncertainty alone is a strong reason pediatric endocrinologists have not adopted romosozumab for children.

How the Adult Dosing Protocol Works (and Why It Cannot Be Extrapolated)

The approved adult regimen is 210 mg administered subcutaneously once monthly for 12 consecutive months, delivered as two 105 mg/1.17 mL injections at the same visit [2]. This dose was selected from Phase 2 data showing a dose-response plateau: 210 mg produced near-maximal lumbar spine BMD gains, while higher doses did not meaningfully improve efficacy [6].

Extrapolating this fixed dose to a child under 12 is not a simple matter of weight adjustment. Several pharmacologic variables differ:

Romosozumab is a monoclonal antibody with a half-life of approximately 12.8 days in adults. Pediatric patients typically exhibit faster clearance of monoclonal antibodies relative to body weight due to higher metabolic rates and different body-composition ratios [7]. Without formal pharmacokinetic studies in children, the drug's exposure-response relationship is unknown. A weight-based dose that achieves adequate sclerostin suppression in a 30 kg child might produce supratherapeutic levels in a 15 kg toddler, or it might fall short entirely. These are not problems that bedside arithmetic can solve.

The 12-month treatment limit in adults exists because bone formation markers (P1NP) return toward baseline by month 9, suggesting the anabolic window has a ceiling [3]. Whether this same temporal pharmacology applies to the actively remodeling pediatric skeleton is unstudied.

Pediatric Bone Conditions Where Romosozumab Has Been Discussed

Three pediatric bone disorders have generated interest in sclerostin inhibition, though none has produced approved pediatric dosing.

Osteogenesis imperfecta (OI). OI types I through IV involve defective collagen synthesis, resulting in fragile bones. Current standard treatment for moderate-to-severe OI in children is intravenous bisphosphonates, primarily pamidronate or zoledronic acid [8]. Preclinical models of OI (the Brtl mouse) treated with sclerostin antibody showed improvements in bone mass and strength, but the collagen defect persisted [9]. A small number of case reports and compassionate-use cases in adolescents (not children under 12) have appeared in conference abstracts, but no peer-reviewed pediatric dosing data have been published.

Idiopathic juvenile osteoporosis (IJO). IJO is a rare, self-limited condition that typically resolves after puberty. Because it resolves spontaneously, the risk-benefit calculus for a drug carrying a boxed cardiovascular warning is unfavorable [10].

Glucocorticoid-induced osteoporosis in children. Children receiving chronic corticosteroids (for conditions like nephrotic syndrome or inflammatory bowel disease) can develop significant bone loss. Bisphosphonates remain the most studied intervention in this population. Romosozumab's anabolic mechanism is theoretically appealing, but the absence of any dose-finding study in children keeps it firmly in the speculative category.

The Cardiovascular Boxed Warning and Pediatric Risk

Romosozumab carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death. In the ARCH trial, major adverse cardiac events (MACE) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group over 12 months [1]. The FDA labeled romosozumab contraindicated in patients who have had a myocardial infarction or stroke within the preceding year [2].

Children under 12 have extremely low baseline cardiovascular event rates, which might seem reassuring. The mechanism behind the cardiovascular signal remains unclear. Some researchers have hypothesized that sclerostin inhibition may affect vascular calcification pathways through Wnt-mediated effects on vascular smooth muscle cells [11]. Whether this mechanism is active in pediatric vasculature is unknown. In the absence of safety data, the boxed warning applies as a precautionary principle, and no institutional review board is likely to approve a trial in young children without compelling preclinical safety signals.

What Alternatives Exist for Pediatric Bone Loss

For clinicians managing bone fragility in children under 12, several evidence-based options exist, none of which involves romosozumab.

Bisphosphonates remain first-line for moderate-to-severe pediatric osteoporosis. Intravenous pamidronate has the longest track record, with published dosing protocols for children as young as infancy in severe OI [12]. Zoledronic acid offers less frequent dosing (every 6 months) and has been studied in children with OI in randomized trials.

Denosumab (Prolia/Xgeva), a RANKL inhibitor, has been used off-label in pediatric OI, though it carries its own complications: rebound vertebral fractures after discontinuation are well-documented in pediatric case series [13]. The Endocrine Society does not recommend denosumab for routine pediatric osteoporosis.

Teriparatide (Forteo), a parathyroid hormone analog, is another anabolic agent that is contraindicated in patients with open epiphyses due to a historical signal of osteosarcoma in rats exposed to high doses during growth. The FDA black-box warning on teriparatide (since relaxed in 2020 for adults) effectively excludes children under 12 from use.

Nutritional and lifestyle optimization (calcium, vitamin D, weight-bearing exercise) should always be addressed before pharmacologic intervention. The Endocrine Society's 2011 guidelines recommend ensuring 25-hydroxyvitamin D levels above 20 ng/mL in children at risk for bone fragility [14].

Monitoring Considerations If Off-Label Pediatric Use Were Pursued

This section does not endorse off-label romosozumab use in children. It outlines what a monitoring framework might include if a pediatric bone specialist were to consider it under an institutional review board-approved protocol or compassionate-use pathway.

Growth velocity would require serial measurement every 3 months, with bone age radiographs at baseline and at 6-month intervals to detect premature physeal changes. Bone turnover markers, specifically P1NP (procollagen type I N-terminal propeptide) for formation and CTX (C-terminal telopeptide) for resorption, would track the anabolic response and help identify the timepoint at which bone formation wanes [15]. DXA scans adjusted for pediatric reference data (Z-scores, not T-scores) would be needed at baseline, 6 months, and 12 months.

Cardiovascular monitoring should include baseline echocardiography and lipid panels, given the adult MACE signal. Any unexplained chest pain, neurologic symptoms, or blood pressure changes should trigger immediate evaluation. Anti-drug antibody testing would also be reasonable, since monoclonal antibodies can provoke neutralizing antibody responses that differ in incidence and clinical impact between adults and children.

Hepatic and renal function panels, complete blood counts, and serum calcium/phosphorus levels round out the standard laboratory surveillance. Hypocalcemia, while uncommon in adult romosozumab trials, could present differently in a child with rapid skeletal turnover.

Regulatory Path Forward for Pediatric Studies

The FDA's 2023 reauthorization of the Best Pharmaceuticals for Children Act (BPCA) and PREA gives the agency tools to request pediatric studies for drugs that might benefit children, even when the original indication is adult-only [16]. To date, no Written Request under BPCA has been issued for romosozumab.

For a pediatric romosozumab trial to become reality, several conditions would likely need to align. First, a specific pediatric population with an unmet need (such as severe OI unresponsive to bisphosphonates) would need to be identified. Second, preclinical toxicology studies in juvenile animal models would need to demonstrate acceptable growth plate safety margins. Third, a dose-finding Phase 1/2 study in adolescents would likely precede any study in children under 12.

The Rare Pediatric Disease Priority Review Voucher program could incentivize Amgen or UCB to pursue this path, but as of May 2026, neither manufacturer has publicly announced plans for pediatric development of romosozumab.

Current Professional Society Positions

The American Academy of Pediatrics (AAP) and the Pediatric Endocrine Society do not include romosozumab in their treatment algorithms for pediatric bone disorders [17]. The Endocrine Society's clinical practice guidelines for osteoporosis management mention romosozumab only in the context of postmenopausal women and men over 50 at high fracture risk [18].

The International Society for Clinical Densitometry (ISCD) 2019 position statement on pediatric DXA addresses bisphosphonate monitoring in children but makes no mention of sclerostin inhibitors [19]. This silence reflects the absence of data rather than an active recommendation against future study.

Clinicians who encounter a child under 12 with severe bone fragility should consult a pediatric bone specialist and consider referral to a center participating in pediatric OI registries, where access to emerging therapies through clinical trials may be possible.